Rights and permissions
About this article
Cite this article
Infliximab not worth it for third-party payers in Canada. Inpharma Wkly. 1334, 7 (2002). https://doi.org/10.2165/00128413-200213340-00012
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128413-200213340-00012